南方财经9月17日电，红日药业(300026.SZ)公告，公司及全资孙公司因税务自查需补缴税款2,516.60万 元及滞纳金867.22万元，合计3,383.82万元，目前已全额缴纳，不涉及行政处罚。该款项计入2025年当 期损益，将直接影响当年归属于上市公司股东的净利润。 ...

格隆汇9月16日丨红日药业(300026.SZ)公布，经自查，公司及全资孙公司需补缴税款2,516.60万元，滞 纳金867.22万元，合计3,383.82万元。截至本公告披露日，上述税款及滞纳金缴纳完毕，本次补缴不涉 及行政处罚。 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-050 天津红日药业股份有限公司（以下简称"公司"）及全资孙公司近期对相关 涉税事项开展自查，需要补缴税款及滞纳金合计3,383.82万元，现将相关情况公 告如下： 一、基本情况 经自查，公司及全资孙公司需补缴税款2,516.60万元，滞纳金867.22万元， 合计3,383.82万元。截至本公告披露日，上述税款及滞纳金缴纳完毕，本次补缴 不涉及行政处罚。 二、对公司的影响 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相 关规定，上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据 追溯调整。公司及全资孙公司补缴上述税款及滞纳金将计入 2025 年当期损益， 对公司 2025 年度归属于上市公司股东的净利润的影响，最终以 2025 年度经审计 的财务报表为准。敬请广大投资者注意投资风险。 特此公告。 天津红日药业股份有限公司 天津红日药业股份有限公司 关于补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 董 事 会 二○二五 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-049 天津红日药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1．本次股东大会无增加、变更、否决提案的情况； 2．本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 天津红日药业股份有限公司（以下简称"公司"）董事会于2025年08月28日 以公告方式向全体股东发出召开2025年第二次临时股东大会的通知。本次股东大 会采取现场投票和网络投票相结合的方式召开。其中，现场会议于2025年09月16 日下午14:30在天津市武清开发区创业总部基地B01号楼公司会议室召开；通过深 圳证券交易所系统进行网络投票的时间为2025年09月16日上午09:15至09:25、 09:30-11:30，下午13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为2025年09月16日09:15至2025年09月16日15:00的任意时间。 出席本次会议的股东及股东代表共 725 ...

北京市康达律师事务所 关于天津红日药业股份有限公司 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 2025 年第二次临时股东大会的法律意见书 康达股会字【2025】第 0397 号 致：天津红日药业股份有限公司 北京市康达律师事务所（以下简称"本所"）接受天津红日药业股份有限 公司（以下简称"公司"）的委托，指派本所律师参加公司 2025 年第二次临时 股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券 ...

Core Viewpoint - The event highlighted the importance of rigorous processes and assessment mechanisms in selecting and managing research partners for drug development [1] Group 1: Company Overview - Hongri Pharmaceutical's president, Lan Wujun, emphasized the company's commitment to scientific and data-driven approaches in developing modern traditional Chinese medicine products [1] - The company aims to develop safe, effective, and high-quality products while adhering to relevant regulations and project progress [1] Group 2: Research and Development - The complexity and professionalism of drug development were acknowledged, with an emphasis on understanding the progress of specific product applications [1] - The company plans to disclose significant advancements to investors through legal information channels at appropriate times [1]

Core Viewpoint - The company aims to enhance profitability and ensure stable development by improving cost efficiency and leveraging its internal capabilities through a comprehensive approach across the entire industry chain [1] Group 1 - The company plans to strengthen the coordination of research, production, and sales [1] - The focus will be on stimulating internal motivation and exploring its potential [1] - The ultimate goal is to maximize profits and lay a solid foundation for steady growth [1]

Core Viewpoint - Tianjin Hongri Pharmaceutical Co., Ltd. held an investor meeting on September 11, 2025, to discuss its semi-annual performance and governance, engaging with investors on various topics [1] Group 1: R&D and Strategy - Investors inquired about the increase in R&D investment in innovative chemical and biological drugs for the first half of 2025, as well as the company's differentiation strategy regarding PD-1/L1 target research [2] - The company emphasized that R&D innovation is a core strategy, acknowledging the lengthy and uncertain nature of new drug development [2] - There were concerns about the company's dual-driven strategy being mere rhetoric, to which the company responded that it is based on concrete actions and long-term planning [2] Group 2: Business Operations and Management - Investors raised questions about the progress and profitability of the collaboration with Chengdu Medical Investment on the Rongcheng Elderly Care Project, with the company advising to refer to periodic reports for updates [2] - Suggestions were made for the company to adopt promotional strategies for its "Shangyimingjia" internet platform, which the company acknowledged [2] - The management's professional background was questioned due to performance declines post the acquisition by Xingcheng Group, with the company asserting compliance with legal and regulatory standards in management appointments [2] Group 3: Financial Performance and Market Management - The company addressed inquiries regarding sales, management appointments, product sales, and R&D progress, stating that it would evaluate single products for policy support to ensure overall effectiveness [2] - On market capitalization management, the company noted that stock prices are influenced by various factors and has established a market value management system to enhance operational efficiency [2] - The company confirmed no significant changes in revenue contribution from various business segments and has no current acquisition plans [2]

Group 1: Company Performance and Financials - The company's net profit decreased by 46.95% year-on-year, while revenue dropped by 6.72% in the first half of 2025 [18] - The revenue from the traditional Chinese medicine formula granules accounted for 46.15% of the company's total revenue in 2024 [10] - The company has not seen significant changes in the contribution weight of various business segments to revenue [9] Group 2: Research and Development - The company emphasizes that innovation in drug development is a long-term process with inherent uncertainties [59] - The clinical trial for the new drug KB has completed phase IIb, but the timeline for further progress remains unclear [59] - The company is committed to optimizing its R&D processes and enhancing its capabilities in drug development [13] Group 3: Market Strategy and Operations - The company is focusing on core businesses, including finished pharmaceuticals, formula granules, and medical devices [12] - The company has established a digital platform for traditional Chinese medicine services, aiming to enhance patient accessibility [22] - The company is actively exploring supply chain optimization through digital transformation [60] Group 4: Investor Relations and Communication - The management acknowledges the concerns of investors regarding the company's performance and is committed to improving transparency [42] - The company has implemented a market value management system to enhance shareholder returns [30] - The management emphasizes the importance of professional responses to investor inquiries during communication events [28]

Core Viewpoint - The event highlighted the development of a comprehensive traditional Chinese medicine (TCM) service ecosystem by Hongri Pharmaceutical, focusing on both online and offline platforms to enhance healthcare services [1] Group 1: Company Initiatives - Hongri Pharmaceutical's president, Lan Wujun, emphasized the establishment of an online TCM service platform "Shangyi Mingjia" and offline chain "Shangyi Mingjia TCM Clinics" to create a unified brand image for TCM healthcare services [1] - The "Shangyi Mingjia" platform has expanded its reach through direct medical institutions and franchise clinics across multiple provinces including Beijing, Tianjin, Hebei, Shandong, Guangdong, and Sichuan [1] - The company is continuously enriching its product and service offerings, innovating application scenarios, and facilitating a transition from preventive care to treatment and rehabilitation, ultimately enhancing patient convenience [1] Group 2: Industry Trends - The initiative reflects a broader trend in the healthcare industry towards integrating traditional medicine with modern healthcare practices, aiming to provide a holistic approach to patient care [1] - The focus on creating a comprehensive service ecosystem indicates a shift in the industry towards more personalized and accessible healthcare solutions [1]